These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33772436)

  • 21. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
    Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
    J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
    Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
    Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.
    Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S
    Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375
    [No Abstract]   [Full Text] [Related]  

  • 24. EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy.
    Liu Y; Scrivano L; Peterson JD; Fens MHAM; Hernández IB; Mesquita B; Toraño JS; Hennink WE; van Nostrum CF; Oliveira S
    Mol Pharm; 2020 Apr; 17(4):1276-1292. PubMed ID: 32142290
    [No Abstract]   [Full Text] [Related]  

  • 25.
    Piramoon M; Hosseinimehr SJ; Omidfar K; Noaparast Z; Abedi SM
    Chem Biol Drug Des; 2017 Apr; 89(4):498-504. PubMed ID: 27650045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
    Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
    J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity.
    Bakherad H; Farahmand M; Setayesh N; Ebrahim-Habibi A
    Life Sci; 2020 Sep; 257():118052. PubMed ID: 32634431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector.
    Noor A; Walser G; Wesseling M; Giron P; Laffra AM; Haddouchi F; De Grève J; Kronenberger P
    BMC Res Notes; 2018 Oct; 11(1):751. PubMed ID: 30348204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.
    Chen T; Liu X; Hong H; Wei H
    J Transl Med; 2020 Oct; 18(1):376. PubMed ID: 33023595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotoxins and nanobody-based immunotoxins: review and update.
    Khirehgesh MR; Sharifi J; Safari F; Akbari B
    J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells.
    Zavoiura O; Brunner B; Casteels P; Zimmermann L; Ozog M; Boutton C; Helms MW; Wagenaar T; Adam V; Peterka J; Metz-Weidmann C; Deschaght P; Scheidler S; Jahn-Hofmann K
    Mol Pharm; 2021 Mar; 18(3):1048-1060. PubMed ID: 33444501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
    Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
    J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.
    Herbst RS; Shin DM
    Cancer; 2002 Mar; 94(5):1593-611. PubMed ID: 11920518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanobody-based cancer therapy of solid tumors.
    Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
    Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.